mali quote - 17nov

Maybe it wasnt possible for you to read this either ...

LONDON (AFX) - Bioglan Pharma PLC remains a 'sell', according to WestLB Panmure's Emma Palmer, who believes that liquidation has to be a strong possibility for the company.

Bioglan's straitened situation, said Palmer, has forced it to relinquish US
rights to one of its potentially most valuable products, Solaraze (licensed from
SkyePharma to a third party)


Research LINESAL1 - plz Im laughing too much already